Amgen (AMGN) Tops Q1 EPS by 16c

Amgen (NASDAQ: AMGN) reported Q1 EPS of $3.98, $0.16 better than the analyst estimate of $3.82. Revenue for the quarter came in at $6.1 billion versus the consensus estimate of $6.12 billion.

GUIDANCE:

Amgen sees FY 2023 EPS of $17.60-$18.70, versus the consensus of $17.72. Amgen sees FY 2023 revenue of $26.2-27.3 billion, versus the consensus of $26.7 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Birchtech Corp. (BCHT) Misses Q2 EPS by 7c
• LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c